310870-76-9

Upstream product

• 81-07-2 saccharin 
• 1515-95-3 p-ethylanisole 
• 104-93-8 p-methylanizole 
• 310870-73-6 (R)-3-((R)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-2-(4-methoxy-benzyl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide 
• 310870-72-5 3(R)-(R)-{1-O,2-O-isopropylidene-1,2-dihydroxyethan-1-yl}-1,2-benzisothiazoline 1,1-dioxide 
• 310870-69-0 3(R)-{1(R),2-dihydroxyethan-1-yl}-1,2-benzisothiazoline 1,1-dioxide 
• 21416-94-4 methyl (E)-3-(2-sulfamoylphenyl)acrylate 
• 310870-67-8 o-aminosulfonyl-trans-cinnamyl alcohol 
• 824-94-2 p-methoxybenzyl chloride 
• 1008-72-6 sodium 2-formylbenzenesulfonate 
• 310870-74-7 3(R)-{1(R),2-dihydroxyethan-1-yl}-2-(4-methoxyphenyl)methyl-1,2-benzisothiazoline 1,1-dioxide 

Downstream Products

• 310870-78-1 (+/-)-3-cyano-2-(4-methoxyphenyl)methyl-1,2-benzisothiazoline 1,1-dioxide 
• 310870-77-0 (+/-)-3-hydroxy-2-(4-methoxyphenyl)methyl-1,2-benzisothiazoline 1,1-dioxide 

Relevant academic research and scientific papers

Efficient imidation of C(sp3)-H bonds adjacent to oxygen atoms of aryl ethers under metal-free conditions

An intermolecular oxidative C-N formation reaction of aryl ethers with pharmacological saccharins was realized under metal-free conditions for the first time. The understanding of the intrinsic characteristics between C(sp3)-H and C(sp2/s

MUCIN SYNTHESIS INHIBITORS

The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.

MUCIN SYNTHESIS INHIBITORS

Abstract of the Disclosure The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (CO